Revel Strengthens Boards

SRF spin-off Revel Pharmaceuticals, a privately held biotechnology company creating therapeutics to reverse and repair damage that results from aging - particularly extracellular crosslinks - has announced recent additions to its Board of Directors and Scientific Advisory Board.
revel_ci

SRF spin-off Revel Pharmaceuticals, a privately held biotechnology company creating therapeutics to reverse and repair damage that results from aging – particularly extracellular crosslinks – has announced recent additions to its Board of Directors and Scientific Advisory Board.

Joining as a member of the Board of Directors is Jennifer Cochran, Ph.D. and joining as a member of the Scientific Advisory Board is Vincent Monnier, Ph.D. “We are thrilled to attract stellar leadership that matches the level of promise of Revel’s mission of attacking diseases of aging,” said Aaron Cravens, Revel co-founder and CEO.

For more information, read the full announcement on Revel’s site.

Share on facebook
Share on twitter
Share on reddit
Share on linkedin
Share on google
Share on email

Latest Posts:

Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

© 2020 SENS Research Foundation – ALL RIGHTS RESERVED

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also

or

You can